WHAT IS CLAIMED IS:

1. A compound of the formula (I) or (II):



(I)



(II)

wherein

m is an integer from 0 to 1;

with the proviso that if m is 0 or 1, then

"HET" in the compound of formula (II) is a stable five- or six-membered monocyclic aromatic ring system composed of carbon atoms and one heteroatom, wherein the heteroatom is selected from the group consisting of N, O and S which may occupy any position in the ring whereby the resulting ring system is stable;

A is selected from the group consisting of -C(O)-, SO_2 and CH_2;

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2, CH as part of an olefin, NR_3, S and O;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

Z is selected from the group consisting of N and CH;

R_1 is one to two substituents independently selected from the group consisting

of hydrogen, alkyl, alkoxy, halogen, aminoalkyl, oxo and nitro;

Ar is selected from naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino or C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different); or phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, C_1-C_8 aralkyl (wherein optionally the alkyl or aryl portions are independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio or hydroxyl), C_1-C_8 aralkoxy (wherein optionally the alkoxy or aryl portions are independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio or hydroxyl), halogen, cyano, hydroxy, amino, nitro, C_1-C_8 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), $(halo)_{1-3}(C_1$-$C_8)$alkylthio, C_1-C_8 alkylsulfonyl, C_1-C_8 alkylthio, C_1-C_8 alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from C_1-C_8 alkyl) or phenyl (optionally substituted with from one to two substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio, or C_1-C_4 alkylsulfinyl);

R_2 is selected from the group consisting of NR_4COAr, NR_4CO-heteroaryl, NR_4Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl, OCH_2-Ar, OCH_2-heteroaryl, SCH_2-Ar and NR_4CH_2Ar;

R_3 is selected from the group consisting of hydrogen, acyl, alkyl, alkoxycarbonyl, alkylsulfonyl and arylsulfonyl;

R_4 is selected from the group consisting of hydrogen and C_1-C_4 alkyl;

R_5 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 wherein
"HET" is selected from the group consisting of thiophene, furan, pyrrole and pyridine;

A is -C(O)-;

Ar is naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from trifluoromethyl, trifluoromethoxy, -NH-C_1-C_4 alkyl or -N-)C_1-C_4 alkyl)$_2$ (wherein the alkyl groups on the amino may be the same or different);

R_2 is NR_4COAr;

R_4 is selected from the group consisting of hydrogen and methyl;

and pharmaceutically acceptable salts thereof.

3. The compound of Claim 1 wherein
R_4 is hydrogen;

and pharmaceutically acceptable salts thereof.

4. The compound of Claim 1 of the formula (III):



(III)

wherein

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2, CH as part of an olefin, NR_3, S and O;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

R_1 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen, amino C_1-C_4 alkyl, oxo and nitro;

R_2 is NHCOAr;

R_3 is selected from the group consisting of hydrogen, acyl, C_1-C_4 alkyl, C_1-C_4 alkylsulfonyl and arylsulfonyl;

R_5 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

and pharmaceutically acceptable salts thereof.

5. The compound of Claim 4 wherein

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2, CH as part of an olefin, O and S;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

A is –C(O)-;

Z is CH;

Ar is phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, C_1-C_8 aralkyl (wherein optionally the alkyl or aryl portions are independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio or hydroxyl), C_1-C_8 aralkoxy (wherein optionally the alkoxy or aryl portions are independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio or hydroxyl), halogen, cyano, hydroxy, amino, nitro, C_1-C_8 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), $(halo)_{1-3}(C_1$-$C_8)$alkylthio, C_1-C_8 alkylsulfonyl, C_1-C_8 alkylthio, C_1-C_8 alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from C_1-C_8 alkyl) or phenyl (optionally substituted with from one to two substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio, or C_1-C_4 alkylsulfinyl);

and pharmaceutically acceptable salts thereof.

6. A compound of the formula (IV):



Formula (IV)

wherein

X is selected from the group consisting of CH_2, S and O;

R_1 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen, amino C_1-C_4 alkyl, oxo and nitro;

R_5 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

R_6 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, phenyl (wherein the phenyl is optionally substituted with from one to two substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated

C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio, or C_1-C_4 alkylsulfinyl); aralkyl (wherein the alkyl or aryl portions are optionally independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio or hydroxyl), aralkoxy (wherein the alkoxy or aryl portions are optionally independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio or hydroxyl), heteroaryl (optionally substituted with one to two substituents independently selected from C_1-C_4 alkyl or halogen), heteroaryl(C_1-C_8)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents selected from C_1-C_8 alkyl), (halo)$_{1-3}$(C_1-C_4)alkylthio and halogen; and

R_7 is independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxyl, C_1-C_6 alkyl, C_1-C_6 alkoxy, fluorinated C_1-C_6 alkyl and combinations thereof, wherein R_7 represent one to four independently selected groups;

and pharmaceutically acceptable salts thereof.

7. The compound of Claim 6 wherein the compound of formula (IV) is selected from a compound of formula (IVa):



Formula (IVa)

wherein

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2, CH as part of an olefin, S and O;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

R_5 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups may be the same or different), trifluoromethyl and trifluoromethoxy;

and pharmaceutically acceptable salts thereof.

8. A compound of formula (I):



(I)

wherein

A is selected from the group consisting of -C(O)-, SO_2 and CH_2;

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2, CH as part of an olefin, NR_3, S, O and SO_2;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

Z is selected from the group consisting of N and CH;

R_1 is one to two substituents independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, aminoalkyl, oxo and nitro;

R_2 is selected from the group consisting of NR_4COAr, NR_4CO-heteroaryl, NR_4Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl, OCH_2-Ar, OCH_2-heteroaryl, SCH_2-Ar and NR_4CH_2Ar;

R_3 is selected from the group consisting of hydrogen, acyl, alkyl, aralkyl, alkoxycarbonyl, alkylsulfonyl, fluorinated alkyl and arylsulfonyl;

Ar is selected from the group consisting of naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from the group consisting of C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl,

fluorinated C_1-C_8 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino and C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different); and phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, C_1-C_8 aralkyl (wherein the alkyl portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxy), C_1-C_8 aralkoxy (wherein the alkoxy portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxy), halogen, cyano, hydroxy, amino, nitro, C_1-C_8 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_8 alkylsulfonyl, C_1-C_8 alkylthio, $(halo)_{1-3}(C_1$-$C_8)$alkylthio, C_1-C_8 alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_8 alkyl and halogen), heteroaryl(C_1-C_8)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C_1-C_8 alkyl) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio and C_1-C_4 alkylsulfinyl);

R_4 is selected from the group consisting of hydrogen and C_1-C_4 alkyl;

R_5 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

and pharmaceutically acceptable salts thereof.

9. The compound of claim 8 wherein A is -C(O)-.

10. The compound of claim 8 wherein Z is CH.

11. The compound of claim 8 wherein R_1 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen and oxo.

12. The compound of claim 8 wherein R_1 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, chlorine, fluorine and oxo.

13. The compound of claim 8 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, C_1-C_8 aralkyl (wherein the alkyl portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents independently selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxy), C_1-C_8 aralkoxy (wherein the alkoxy portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents independently selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxy), halogen, cyano, hydroxy, amino, nitro, C_1-C_8 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_8 alkylsulfonyl, C_1-C_8 alkylthio, $(halo)_{1-3}(C_1$-$C_8)$alkylthio, C_1-C_8 alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_8 alkyl and halogen), heteroaryl$(C_1$-$C_8)$alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C_1-C_8 alkyl) and phenyl (optionally substituted with from one to two substituents independently

selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio and C_1-C_4 alkylsulfinyl).

14. The compound of claim 8 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, halogen, hydroxy, $(halo)_{1-3}(C_1$-$C_8)$alkylthio, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_8 alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen and hydroxy).

15. The compound of claim 8 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, halogen, hydroxy, $(halo)_{1-3}(C_1$-$C_4)$alkylthio, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_4 alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen and hydroxy).

16. The compound of claim 8 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, halogen, hydroxy and $(halo)_{1-3}(C_1$-$C_4)$alkylthio; and, optionally substituted with from one to two substituents independently selected from the group consisting of heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of

C_1-C_4 alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen and hydroxy).

17. The compound of claim 8 wherein R_2 is selected from the group consisting of NR_4COAr, NR_4CO-heteroaryl, NR_4Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl and NR_4CH_2Ar.

18. The compound of claim 8 wherein R_2 is selected from NR_4COAr.

19. The compound of claim 8 wherein R_2 is selected from NHCOAr.

20. The compound of claim 8 wherein R_3 is selected from the group consisting of hydrogen, acyl, C_1-C_8 alkyl, ar(C_1-C_8)alkyl, C_1-C_8 alkoxycarbonyl, C_1-C_8 alkylsulfonyl, fluorinated(C_1-C_8) alkyl and arylsulfonyl.

21. The compound of claim 8 wherein R_3 is selected from the group consisting of hydrogen, acyl, C_1-C_4 alkyl, ar(C_1-C_4)alkyl and trifluoro(C_1-C_4)alkyl.

22. The compound of claim 8 wherein R_3 is selected from the group consisting of hydrogen, formyl, methyl, isopropyl, benzyl and trifluoroethyl.

23. The compound of claim 8 wherein R_5 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy.

24. The compound of claim 8 wherein R_5 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, chlorine, fluorine, hydroxy, dimethylamino and trifluoromethyl.

25. The compound of claim 6 wherein R_6 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, phenyl (wherein the phenyl is optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio and C_1-C_4 alkylsulfinyl); heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_4 alkyl and halogen), heteroaryl(C_1-C_8)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C_1-C_8 alkyl), (halo)$_{1\text{-}3}$(C_1-C_4)alkylthio and halogen.

26. The compound of claim 6 wherein R_6 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen and hydroxy), heteroaryl (optionally substituted with one to two substituents independently selected from C_1-C_4 alkyl), (halo)$_{1\text{-}3}$(C_1-C_4)alkylthio and halogen.

27. The compound of claim 6 wherein R_6 is selected from the group consisting of hydrogen, methyl, phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of methyl, methoxy, fluorine and hydroxy), thienyl (optionally substituted with methyl), difluoromethylthio, fluorine, chlorine and iodine.

28. The compound of claim 6 wherein R_7 is one to three substituents independently selected from the group consisting of hydrogen, fluorine,

chlorine, iodine, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy and fluorinated C_1-C_6 alkyl.

29. The compound of claim 6 wherein R_7 is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, C_1-C_4 alkyl, C_1-C_4 alkoxy and fluorinated C_1-C_4 alkyl.

30. The compound of claim 6 wherein R_7 is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, C_1-C_2 alkyl, C_1-C_2 alkoxy and fluorinated C_1-C_2 alkyl.

31. The compound of claim 6 wherein R_7 is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, methyl, methoxy and trifluoromethyl.

32. The compound of Claim 1 selected from the group consisting of

10-[4-[[(2-Biphenyl)carbonyl]amino]benzoyl]-10,11-dihydro-5H-piperidino[2,1-c][1,4]benzodiazepine;

10-[4-[[(2-Biphenyl)carbonyl]amino]benzoyl]-10,11-dihydro-5H-(tetrahydropyridino)[2,1-c] [1,4]benzodiazepine;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-(4-Hydroxyphenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-4-hydroxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-(3-Hydroxyphenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-5-hydroxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-2-thienyl)-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,6-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*R*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3,4,5-Tetrafluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Chloro-5-trifluoromethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Fluoro-3-chloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(Difluoromethylthio)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-5-oxo-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[2-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-methoxy-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-fluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(9-chloro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8,9-difluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-methyl-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-chloro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(8-fluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(10-methyl-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-3,5-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Iodo-3-methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-3,5-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-3-iodo-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(2-Fluoro-phenyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-*N*-[3-dimethylamino-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

and pharmaceutically acceptable salts thereof.

33. The compound of Claim 1 selected from the group consisting of

10-[4-[[(2-Biphenyl)carbonyl]amino]benzoyl]-10,11-dihydro-1,2-methanopyrrolidino[2,1-c][1,4]benzodiazepine;

(*RS*)-2-(3-Thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Thienyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-

a][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Thienyl)-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(2-Thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-2-thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-2-thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2,2-dioxo-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-benzyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-formyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-isopropyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,6-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-

[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-trifluoromethyl-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[2-methyl-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-(2,2,2-trifluoroethyl)-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3,4,5-Tetrafluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-3-chloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,6-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-3-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-4-methoxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-methoxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

and pharmaceutically acceptable salts thereof.

34. A compound of the formula (V):



(V)

35. A compound of the formula (VI):



(VI)

36. A compound of the formula (VII):



Formula (VII)

37. A compound of the formula (VIII):



Formula (VIII)

38. A compound of the formula (IX):



Formula (IX)

wherein R_3 is selected from the group consisting of hydrogen, acyl, alkyl, aralkyl, alkoxycarbonyl, alkylsulfonyl, fluorinated alkyl and arylsulfonyl.

39. The compound of claim 38 wherein R_3 is selected from the group consisting of hydrogen, acyl, alkyl, aralkyl and trifluoroalkyl.

40. The compound of claim 38 wherein R_3 is selected from the group consisting of hydrogen, formyl, methyl, isopropyl, benzyl and trifluoroethyl.

41. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.

42. A pharmaceutical composition made by mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.

43. A pharmaceutical composition made by granulating a compound of Claim 1 and a pharmaceutically acceptable carrier.

44. A pharmaceutical composition comprising a pharmaceutically

acceptable carrier and a compound of Claim 8.

45. A pharmaceutical composition made by mixing a compound of Claim 8 and a pharmaceutically acceptable carrier.

46. A pharmaceutical composition made by granulating a compound of Claim 8 and a pharmaceutically acceptable carrier.

47. A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.

48. The method of Claim 47, wherein the condition is congestive heart failure.

49. The method of Claim 47, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

50. A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 8.

51. The method of Claim 50, wherein the condition is congestive heart failure.

52. The method of Claim 50, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

53. A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 6.

54. The method of Claim 53, wherein the condition is congestive heart failure.

55. The method of Claim 53, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.